Fulgent Genetics Inc (FLGT)
Return on equity (ROE)
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -167,825 | 143,403 | 507,364 | 214,310 | -411 |
| Total stockholders’ equity | US$ in thousands | 1,136,100 | 1,266,680 | 1,158,750 | 569,387 | 82,777 |
| ROE | -14.77% | 11.32% | 43.79% | 37.64% | -0.50% |
December 31, 2023 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-167,825K ÷ $1,136,100K
= -14.77%
Fulgent Genetics Inc's return on equity (ROE) has displayed significant fluctuations over the past five years. In 2023, the ROE was negative at -14.77%, indicating that the company generated a net loss relative to its shareholders' equity. This represents a substantial decline from the previous year's ROE of 11.32%.
The year 2021 saw a robust ROE of 43.79%, reflecting strong profitability and efficient utilization of shareholders' equity. This marked improvement from 2020, when the ROE was at 37.64%.
In 2019, Fulgent Genetics Inc posted a slightly negative ROE of -0.50%, suggesting potential inefficiencies in generating returns for shareholders.
Overall, the trend in ROE for Fulgent Genetics Inc has been mixed, with periods of strong profitability and efficiency in capital utilization interspersed with instances of suboptimal performance and losses. This metric is essential for evaluating a company's ability to generate profits from its equity base and warrants further investigation into the factors driving these fluctuations.
Peer comparison
Dec 31, 2023